Alpha Emitter Market Size to Worth USD 1,488.02 Million By 2033

The alpha emitter market size is poised to grow by USD 1,488.02 million by 2033 from USD 581.6 million in 2023, exhibiting a CAGR of 9.90% during the forecast period 2024 to 2033.

Key Takeaways

• North America contributed more than 44% of market share in 2023.
• Asia-Pacific is estimated to expand at the fastest CAGR between 2024 and 2033.
• By type of radionuclide, the actinium (Ac-225) segment has held the largest market share of 38% in 2023.
• By type of radionuclide, the radium (Ra-223) segment is anticipated to grow at a remarkable CAGR of 10.16% between 2024 and 2033.
• By application, the bone metastases segment generated over 36% of the market share in 2023.
• By application, the prostate cancer segment is expected to expand at the fastest CAGR over the projected period.
• By source, the natural sources segment generated over 54% of the market share in 2023.
• By source, the artificially produced sources segment is expected to expand at the fastest CAGR over the projected period.

The Alpha Emitter market is a dynamic sector characterized by the use of alpha-emitting radionuclides for various applications. These radionuclides emit alpha particles during radioactive decay, making them valuable for medical, industrial, and research purposes. The market encompasses a range of products and services related to the production, distribution, and application of alpha emitters.

Get a Sample Report: https://www.precedenceresearch.com/sample/3690

Growth Factors

The growth of the Alpha Emitter market is fueled by advancements in medical treatments, particularly in the field of oncology. Alpha emitters play a crucial role in targeted alpha-particle radiotherapy, offering a more precise and effective approach to cancer treatment. Additionally, increasing applications in industrial processes, such as nuclear power generation and oil exploration, contribute to the market’s expansion. The growing emphasis on personalized medicine and the continuous development of alpha-emitting radionuclides further drive market growth.

Alpha Emitter Market Scope

Read More: Metaverse in E-commerce Market Size to Rise USD 936.28 Bn By 2033

Opportunities

Opportunities in the Alpha Emitter market lie in the expanding scope of alpha-particle-based therapies for various diseases beyond cancer. Research and development efforts to discover new alpha emitters with enhanced properties open avenues for innovation. Collaborations between healthcare institutions, research centers, and industry players present opportunities for the integration of alpha emitters into novel treatment modalities. Moreover, the rising demand for radiopharmaceuticals and diagnostic tools provides a favorable environment for market expansion.

Challenges

Despite the promising outlook, the Alpha Emitter market faces challenges related to regulatory frameworks and safety concerns. The handling and transportation of alpha-emitting materials require stringent protocols to mitigate potential risks. Regulatory approvals for new alpha emitters may pose obstacles, impacting the speed of product commercialization. Additionally, the high costs associated with research, development, and production may present challenges, particularly for smaller companies entering the market.

Alpha Emitter Market Companies

• Alpha Tau Medical Ltd.
• NorthStar Medical Radioisotopes
• IBA Worldwide
• RadioMedix
• Orano Med
• Bayer AG
• Novartis International AG
• Actinium Pharmaceuticals, Inc.
• Fusion Pharmaceuticals Inc.
• Eckert & Ziegler
• Telix Pharmaceuticals Limited
• Curium Pharma
• AAA (Advanced Accelerator Applications)
• Isotopen Technologien München AG (ITM)
• Nordion (Canada) Inc.

Data Sources and Methodology

To gather comprehensive insights on the Global Alpha emitter Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.

We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Alpha emitter Market.

The most resonating, simple, genuine, and important causes because of which you must decide to buy the Alpha emitter market report exclusively from precedence research

• The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2023 to 2032.

Key Features of the Report:

• Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
• Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
• Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.

Market Segmentation:

By Type of Radionuclide

• Radium (Ra-223)
• Actinium (Ac-225)
• Lead (Pb-212)
• Astatine-211
• Bismuth-213
• Others

By Application

• Bone Metastases
• Prostate Cancer
• Neuroendocrine Tumors
• Ovarian Cancer
• Others

By Source

• Natural Sources (Uranium-238, Radium-226)
• Artificially Produced Sources (Plutonium, Americium, Curium, Californium)
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Reasons to Consider Purchasing the Report:

• Enhance your market research capabilities by accessing this comprehensive and precise report on the global Alpha emitter market.
• Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
• Benefit from in-depth research and analysis of the latest trends shaping the global Alpha emitter market.
• Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Alpha emitter market.
• Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
• Discover not only the cutting-edge technological advancements in the global Alpha emitter market but also the strategic plans of industry leaders.

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Alpha Emitter Market 

5.1. COVID-19 Landscape: Alpha Emitter Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Alpha Emitter Market, By Type of Radionuclide

8.1. Alpha Emitter Market, by Type of Radionuclide, 2024-2033

8.1.1 Radium (Ra-223)

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Actinium (Ac-225)

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Lead (Pb-212)

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Astatine-211

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Bismuth-213

8.1.5.1. Market Revenue and Forecast (2021-2033)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Alpha Emitter Market, By Application

9.1. Alpha Emitter Market, by Application, 2024-2033

9.1.1. Bone Metastases

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Prostate Cancer

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Neuroendocrine Tumors

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Ovarian Cancer

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Alpha Emitter Market, By Source 

10.1. Alpha Emitter Market, by Source, 2024-2033

10.1.1. Natural Sources (Uranium-238, Radium-226)

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Artificially Produced Sources (Plutonium, Americium, Curium, Californium)

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Alpha Emitter Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.1.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.3. Market Revenue and Forecast, by Source (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.5.3. Market Revenue and Forecast, by Source (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.2.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.3. Market Revenue and Forecast, by Source (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.5.3. Market Revenue and Forecast, by Source (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.6.3. Market Revenue and Forecast, by Source (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.7.3. Market Revenue and Forecast, by Source (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.3.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.3. Market Revenue and Forecast, by Source (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.5.3. Market Revenue and Forecast, by Source (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.6.3. Market Revenue and Forecast, by Source (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.7.3. Market Revenue and Forecast, by Source (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.5.3. Market Revenue and Forecast, by Source (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.6.3. Market Revenue and Forecast, by Source (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.7.3. Market Revenue and Forecast, by Source (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.3. Market Revenue and Forecast, by Source (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.5.3. Market Revenue and Forecast, by Source (2021-2033)

Chapter 12. Company Profiles

12.1. Alpha Tau Medical Ltd.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. NorthStar Medical Radioisotopes

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. IBA Worldwide

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. RadioMedix

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Orano Med

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Bayer AG

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Novartis International AG

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Actinium Pharmaceuticals, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Fusion Pharmaceuticals Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Eckert & Ziegler

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Unlocking Market Insights through Data Excellence

The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.

 

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

Precedence Statistics – Empowering Your Data Insights

 

Contact Us

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com